Liraglutide, semaglutide, and tirzepatide are all GLP-1 agonists resulting in significant weight loss in RCTs
The potential role of adjunctive bone-protective therapies - including calcium and vitamin D supplementation, weight-bearing exercise, and, in selected high-risk cases, pharmacologic agents such as bisphosphonates - should be considered on an individual basis, though no evidence specifically addresses this question in MC4R -deficient patients
Managing the washout period effectively is crucial for a smooth transition, allowing Semaglutide GLP-1 to clear from your system and reducing the risk of interactions and side effects
But knowing what to expect, and how to manage it, makes the experience dramatically more tolerable
Who Should NOT Take GLP-1 Medications Being honest about who isnt a good candidate is part of providing responsible care